VYNE Therapeutics Announces Positive First-In-Human Pharmacokinetic and Hematology Data from Phase 1a Single and Multiple Ascending Dose Trial for Novel Pan-Bromodomain BET Inhibitor VYN201
In4Derm announces a £1.6m pre-Series A funding round to support the continued development and expansion of its pipeline of first-in-class anti-inflammatory and orphan indications therapeutics
University of Dundee researchers hope to turn their spinout venture into a biotech company worth hundreds of millions of pounds by helping to treat people with eczema, rheumatoid arthritis and other inflammatory conditions
